These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3861196)

  • 1. Treatment of CML blast crisis with low dose ARA-C.
    di Raimondo F; Milone G; Guglielmo P; Cacciola E; Giustolisi R
    Br J Haematol; 1985 Aug; 60(4):773-4. PubMed ID: 3861196
    [No Abstract]   [Full Text] [Related]  

  • 2. 5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine.
    Galmarini CM; Cros E; Graham K; Thomas X; Mackey JR; Dumontet C
    Haematologica; 2004 May; 89(5):617-9. PubMed ID: 15136231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose cytosar in the treatment of chronic granulocytic leukaemia--blast crisis.
    Kumar L; Kochipillai V; Dua H
    N Z Med J; 1987 Jan; 100(816):31. PubMed ID: 3468410
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.
    Iacoboni SJ; Plunkett W; Kantarjian HM; Estey E; Keating MJ; McCredie KB; Freireich EJ
    J Clin Oncol; 1986 Jul; 4(7):1079-88. PubMed ID: 3459811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
    Yang GS; McCulloch EA
    Hematol Pathol; 1992; 6(3):125-30. PubMed ID: 1385380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Small doses of ARA-C in the treatment of myeloblastic leukemia and blast crisis of myelocytic leukemia].
    Górski J; Kicińska M; Cenian E
    Acta Haematol Pol; 1984; 15(3-4):167-70. PubMed ID: 6598941
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia.
    Riddell S; Appelbaum FR; Buckner CD; Stewart P; Clift R; Sanders J; Storb R; Sullivan K; Thomas ED
    J Clin Oncol; 1988 Apr; 6(4):576-82. PubMed ID: 3282031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study.
    Fleming RA; Capizzi RL; Rosner GL; Oliver LK; Smith SJ; Schiffer CA; Silver RT; Peterson BA; Weiss RB; Omura GA
    Cancer Chemother Pharmacol; 1995; 36(5):425-30. PubMed ID: 7634384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High doses of cytosine arabinoside in the treatment of refractory leukemia].
    Klener P; Háber J; Kolesková E
    Sb Lek; 1987 Sep; 89(8-9):271-5. PubMed ID: 3478794
    [No Abstract]   [Full Text] [Related]  

  • 10. The management of blastic crisis of chronic myeloid leukaemia with thioguanine, rubidomycin, ARA C and prednisone (TRAP regimen).
    Resegotti L; Falda M; Rossi M; Infelise VE
    Panminerva Med; 1973 Sep; 15(9):275-7. PubMed ID: 4533778
    [No Abstract]   [Full Text] [Related]  

  • 11. Sensitivity of myeloid progenitor cells in healthy subjects and patients with chronic myeloid leukemia to chemotherapeutic agents.
    Spiro TE; Mattelaer MA; Efira A; Stryckmans P
    J Natl Cancer Inst; 1981 Jun; 66(6):1053-9. PubMed ID: 6941040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
    Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship of [3H]Ara-C incorporation and response to therapy with high-dose Ara-C in AML patients: a Leukemia Intergroup study.
    Raza A; Gezer S; Anderson J; Lykins J; Bennett J; Browman G; Goldberg J; Larson R; Vogler R; Preisler HD
    Exp Hematol; 1992 Nov; 20(10):1194-200. PubMed ID: 1426099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic studies on possible improvement of cytosine arabinoside treatment.
    Mejer J
    Scand J Clin Lab Invest; 1982 Sep; 42(5):401-6. PubMed ID: 6961505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN; Fernández-Jurado A; Martino ML; Diéguez JC; Moreno MV; Quesada JA; Polo B; Cañavate M; Amian A; Prados D
    Sangre (Barc); 1998 Feb; 43(1):35-9. PubMed ID: 9580427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete cytogenetic but not molecular remission in a patient with myeloid blast crisis of chronic myeloid leukemia treated with carboplatin and ara-C.
    Pérez-Simón JA; Caballero MD; Hernandez-Rivas JM; Chillón C; García-Isidoro M; San Miguel JF
    Haematologica; 1997; 82(5):604-5. PubMed ID: 9407733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The blast crisis of chronic granulocytic leukaemia: a new approach to treatment.
    Schey SA; Greene ML; Ardeman S; Ruddell K
    Br J Haematol; 1985 Jan; 59(1):190-2. PubMed ID: 3855645
    [No Abstract]   [Full Text] [Related]  

  • 18. [Results of high-dose cytarabine therapy. A review].
    Gassmann W; Schmitz N; Löffler H
    Onkologie; 1985 Feb; 8(1):8-15. PubMed ID: 3885125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias.
    Raza A; Ucar K; Preisler HD; Mayers G
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):9-19. PubMed ID: 3892706
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute tumor lysis syndrome in a patient with chronic myelogenous leukemia in blast crisis: role of high-dose Ara-C.
    Przepiorka D; Gonzales-Chambers R
    Bone Marrow Transplant; 1990 Oct; 6(4):281-2. PubMed ID: 2085702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.